Dominic Pilon, MA

Comparison of Real-World Healthcare Resource Utilization Among Advanced Therapy-Experienced Patients With Ulcerative Colitis Initiated on Ustekinumab or Vedolizumab

1 Analysis Group Inc., Montréal, Quebec, Canada; 2 Janssen Scientific Affairs, LLC., Horsham, Pennsylvania, United States.

Aditi Shah , MA;

Jill Korsiak ;

Patrick Lefebvre , MA;

Caroline Kerner ;

Dominic Pilon , MA;

Maryia Zhdanava , MA;

Sumesh Kachroo ;

Porpong Boonmak ;

Sabree Burbage ;

01/11/2024

Prevalence of Pre-existing Conditions for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies among Patients with Treatment-Resistant Depression

BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe ph...

Leslie Citrome , MD;

Laura Morrison , MPH;

John J. Sheehan , PhD, MBA, RPh;

Carmine Rossi , PhD;

Maryia Zhdanava , MA;

Oliver Lopena , PharmD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Swapna Karkare , MS;

10/19/2020

Treatment Persistence Among Anti-TNF-Experienced Patients With Ulcerative Colitis Switching to Ustekinumab or Cycling to Another Anti-TNF Agent

1 Analysis Group Inc., Montréal, Quebec, Canada; 2 Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States.

Maryia Zhdanava , MA;

Sumesh Kachroo ;

Porpong Boonmak ;

Sabree Burbage ;

Aditi Shah , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Bridget Godwin ;

01/11/2024

Medication Adherence, Healthcare Resource Utilization, and Costs Among Medicaid Beneficiaries With Schizophrenia Treated With Once-monthly Paliperidone Palmitate or Once-every-three-months Paliperidone Palmitate

Background: Antipsychotics with reduced dosing frequency may improve adherence and clinical outcomes for patients with schizophrenia. This study compared adherence, persistence, healthcar...

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Kruti Joshi , MPH, MD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Aurelie Cote ;

Maude Vermette-Laforme , BSc;

10/08/2020

Cluster Analysis of Care Pathways in Major Depressive Disorder With Suicidal Ideation or Probable Suicide Attempt

BACKGROUND: To understand heterogeneity among the population with major depressive disorder (MDD) and suicidal ideation (SI) or attempt (SA) (MDD+SI/SA), clusters were identified through ...

Laura Morrison , MPH;

Maryia Zhdanava , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Cheryl Neslusan , PhD;

Tom Cornwall , PhD;

Maude Vermette-Laforme , BSc;

Abigail Nash , MD, PhD;

10/08/2020

Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting

BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited. METHODS: Adu...

Laura Morrison , MPH;

Swapna Karkare , MS;

Abigail Nash , MD, PhD;

Maryia Zhdanava , MA;

Aditi Shah , MA;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

10/08/2020

Economic Burden of Treatment Resistant Depression in Privately Insured US Patients With Behavioral Comorbidities

BACKGROUND: Incremental economic burden of treatment resistant depression (TRD) in patients with behavioral comorbidities is largely unknown.

Craig Nelson , MD;

Carmine Rossi , PhD;

Ella Daly , MB, BCh, BAO;

Maryia Zhdanava , MA;

Harsh Kuvadia ;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

11/22/2019

Prevalence, Incidence and Economic Burden of Schizophrenia Among Medicaid Beneficiaries

Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...

Charmi Patel , BS , RN, BSN, MPH;

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Patrick Lefebvre , MA;

Aurélie Côté-Sergent , MSc;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

11/22/2019

Recent Patterns of Relapse and Associated Costs in Schizophrenia Patients Initiating Atypical Antipsychotics

BACKGROUND: Data on the burden associated with schizophrenia relapse within the new treatment landscape is scarce. This study aims to identify relapse in schizophrenia and update their as...

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Charmi Patel , BS , RN, BSN, MPH;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Maria-Helene Lafeuille , MA;

Aurélie Côté-Sergent , MSc;

11/22/2019

Real-World Outcomes Post-Transition to Once-Every-Three-Month Paliperidone Palmitate in Patients With Schizophrenia Within US Commercial and Managed Care Plans

Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...

Antoine C. El Khoury , PhD;

Bruno Emond , MA;

Maryia Zhdanava , MA;

Kruti Joshi , MPH, MD;

Charmi Patel , BS , RN, BSN, MPH;

Patrick Lefebvre , MA;

Laura Morrison , MPH;

Dominic Pilon , MA;

Neeta Tandon , MA;

03/01/2019